Awareness Survey, Safety Measures and Precautions to Combat Tomato Fever- A Prospective Observational Study
Abstract
Background: - A Prospective study was carried out through survey to make sure people were aware of the ongoing endemic tomato flu among children under the of 5 years. To take precaution and break the chain with infected patients.
Objective: - To create awareness among targeted population.
Design: - Survey analysis from prospective cohort studies.
Participants: - Healthcare workers, Medical students and others.
Full text article
Generated from XML file
References
1) Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 45:558–72. doi: 10.1038/nrc3090
2) Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. (2016) 45:129–38. doi: 10.1016/j.ctrv.2016.03.002
3) Ma, C. X, Sparano, J. A. Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: Endocrine therapy and targeted agents. In:Post TW, ed.UpToDate;2022. Accessed February 7, 2022. https://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy-and-targeted-agents
4) Schettini F, De Santo I, Rea CG, et al. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol. 2018;8:608. Published 2018 Dec 12. doi:10.3389/fonc.2018.00608
5) Wilson BE, Mok K, Kiely BE, Nguyen R, Moylan E. Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer. Intern Med J. 2019;49(11):1438-1442. doi:10.1111/imj.14629
6) Ettl J. Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors [published correction appears in Breast Care (Basel). 2020 Feb;15(1):102]. Breast Care (Basel). 2019;14(2):86-92. doi:10.1159/000499534
7) Gupta S, Caza T, Herrmann SM, Sakhiya VC, Jhaveri KD. Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors. Kidney Int Rep. 2021;7(3):618-623. Published 2021 Dec 8. doi:10.1016/j.ekir.2021.11.033
8) Goetz MP, Okera M, Wildiers H, et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021;186(2):417-428. doi:10.1007/s10549-020-06029-y
9) Chappell JC, Turner PK, Pak YA, et al. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019;105(5):1187-1195. doi:10.1002/cpt.1296
10) Gulturk I, Yilmaz M, Ozmen A, Tacar SY, Erdal GS, Tural D. Ribociclib induced acute kidney injury: A case report. J Oncol Pharm Pract. 2021;27(8):2023-2026. doi:10.1177/10781552211007202
11) Pabla N, Gibson AA, Buege M, et al. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015;112(16):5231-5236. doi:10.1073/pnas.1424313112
2) Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. (2016) 45:129–38. doi: 10.1016/j.ctrv.2016.03.002
3) Ma, C. X, Sparano, J. A. Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: Endocrine therapy and targeted agents. In:Post TW, ed.UpToDate;2022. Accessed February 7, 2022. https://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy-and-targeted-agents
4) Schettini F, De Santo I, Rea CG, et al. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol. 2018;8:608. Published 2018 Dec 12. doi:10.3389/fonc.2018.00608
5) Wilson BE, Mok K, Kiely BE, Nguyen R, Moylan E. Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer. Intern Med J. 2019;49(11):1438-1442. doi:10.1111/imj.14629
6) Ettl J. Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors [published correction appears in Breast Care (Basel). 2020 Feb;15(1):102]. Breast Care (Basel). 2019;14(2):86-92. doi:10.1159/000499534
7) Gupta S, Caza T, Herrmann SM, Sakhiya VC, Jhaveri KD. Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors. Kidney Int Rep. 2021;7(3):618-623. Published 2021 Dec 8. doi:10.1016/j.ekir.2021.11.033
8) Goetz MP, Okera M, Wildiers H, et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021;186(2):417-428. doi:10.1007/s10549-020-06029-y
9) Chappell JC, Turner PK, Pak YA, et al. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019;105(5):1187-1195. doi:10.1002/cpt.1296
10) Gulturk I, Yilmaz M, Ozmen A, Tacar SY, Erdal GS, Tural D. Ribociclib induced acute kidney injury: A case report. J Oncol Pharm Pract. 2021;27(8):2023-2026. doi:10.1177/10781552211007202
11) Pabla N, Gibson AA, Buege M, et al. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015;112(16):5231-5236. doi:10.1073/pnas.1424313112
Authors
Paul, P. ., Nath, R. ., & Gupta, S. . (2022). Awareness Survey, Safety Measures and Precautions to Combat Tomato Fever- A Prospective Observational Study. Journal of Current Medical Research and Opinion, 5(08), 1353−1365. Retrieved from https://cmro.in/index.php/jcmro/article/view/527
Copyright and license info is not available